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OBJECTIVE: To compare post-treatment costs across alterna-
tive antipsychotics in the treatment of bipolar disorder (BD).
METHODS: Data from a commercial health plan from July 1,
2003 to June 30, 2006 were used to identify non-institutionalized
patients with bipolar disorder (ICD-9 296.4-296.8) but no
history of schizophrenia (ICD-9 295.xx). Patients initiating treat-
ment using a typical antipsychotic (TAP), atypical antipsychotic
(AAP: aripiprazole, olanzapine, quetiapine, risperidone or
ziprasidone), mood stabilizer or antidepressant were included.
Episodes were divided into three categories: restarting treatment
after a break in drug therapy >15 days with the drug used in the
previous episode, switching therapy with or without a break in
treatment, and augmentation therapy. First observed episodes
were excluded from the analysis due to uncertainty concerning
the patient’s prior treatment history. A total of 106,447 episodes
were included in the analyses using ordinary least squares (OLS)
regression models of post-treatment cost adjusting for age,
gender, geographic region, drug use history, prior medical care
use, bipolar disorder diagnosis and co-morbid medical condi-
tions. RESULTS: Average total post-treatment cost measured
across all episode types ranged from $17,837 (olanzapine) to
$22,292 (ziprasidone). OLS results found augmentation episodes
to be signiﬁcantly more costly than restart episodes (+$6836,
p < 0.0001) or switching episodes (+$4109, p < 0.0001). AAPs
were found to be more costly relative to TAP in patients restart-
ing therapy and these estimates were signiﬁcant for quetiapine
(+$3126, p < 0.01) and ziprasidone (+$4811, p < 0.05). Patients
initiating augmentation episodes with an AAP were also con-
sistently more costly relative to TAP, again signiﬁcantly so
for quetiapine (+$2534, p < 0.05) and ziprasidone (+$2846,
p < 0.05). However, most AAPs achieved signiﬁcantly lower total
costs relative to TAP for switching episodes ranging from -$1817
for ziprasidone (p > 0.05) to -$7632 (p < 0.0001) for olanzap-
ine. CONCLUSION: In a commercially-insured population,
AAPs are only associated with lower total post-treatment costs in
patients with bipolar disorder who switch therapies.
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OBJECTIVE: To compare one-year post treatment costs across
alternative antipsychotics in the treatment of schizophrenia.
METHODS: Data from a commercial health plan from July 1,
2003 to June 30, 2006 were used to identify non-institutionalized
patients with schizophrenia (ICD-9 codes 295.xx) who initiated
treatment a typical antipsychotic (TAP), atypical antipsychotic
(AAP: aripiprazole, olanzapine, quetiapine, risperidone or ziprasi-
done), mood stabilizer or antidepressant. Episodes were divided
into three categories: restarting treatment after a break
in drug therapy >15 days with the drug used in the previous
episode, switching therapy with or without a break in treatment,
and augmentation therapy. First observed episodes were excluded
from the analysis due to uncertainty concerning the patient’s prior
treatment history. A total of 21,876 episodes were included in the
analyses using ordinary least squares (OLS) regression models of
post-treatment costs adjusting for age, gender, geographic region,
drug use history, prior medical care use, schizophrenia diagnosis
and co-morbid medical conditions. RESULTS: Average total cost
measured across all episodes ranged from $22,804 for TAPs to
$32,357 for mood stabilizers. Augmentation episodes were esti-
mated to be signiﬁcantly more costly than switching episodes
(+$4222, p < 0.0001) or restart episodes (+$6970, p < 0.0001).
There is considerable variability in total cost across medications.
However, in this commercially insured population, there is no
signiﬁcant difference in post-treatment costs between patients
receiving individual AAPs and TAP. Patients with schizophrenia
treated with mood stabilizers were signiﬁcantly more costly than
TAP patients for restart episodes (+$4951, p < 0.05) and augmen-
tation episodes (+$2990, p < 0.05). CONCLUSION: In a
commercially-insured population, there are no signiﬁcant differ-
ences in total post-treatment costs for AAPs patients relative to
TAPs patients. Treating patients with schizophrenia with a mood
stabilizer may lead to signiﬁcantly higher cost.
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OBJECTIVE: Long hospital-stay of psychiatric patients is recog-
nized as a problem in Japan compared with the western coun-
tries. In order to address this issue, the Japanese government
initiated a reform plan in 2004 to make the beds largely down-
sized in the next decade, and raised the ofﬁcial fees of hospital-
ization to make a shift from out-patient to in-patient care. The
aim of our study is to estimate how such a shift can affect and
project the total costs of psychiatric care in a hospital when the
hospital complies with the government new plan. METHODS: A
system dynamics model for computing simulation was developed
to estimate the total medical costs per hospital over a three-year
period, employing the data from the published literature such as
The 2006 Comprehensive Survey Report of the Japanese Asso-
ciation of Psychiatric Hospitals, etc. The model consists of four
compartments for one out-patient care unit and three types of
in-patient units such as short-term, mid-term and long-term care.
The ﬂows of patients and the relevant costs were analyzed and
ﬁgured out alongside the compartments in the model. Hypotheti-
cal scenarios were simulated, assuming different rates of in- and
out-patients ﬂows. RESULTS: The simulated estimation resulted
in the highest cost, $27,933,166, of one scenario with maximiz-
ing both a discharge rate of long-hospitalized patients and an
acquisition rate of new out-patients. On the contrary, the lowest
cost, $22,789,521, was identiﬁed in another scenario with no
acceleration for discharge of long-hospitalized patients and no
acquisition of new out-patients. CONCLUSION: A system
dynamics simulation suggested that the government new policy
for psychiatric care does not lead to cost-saving in a hospital
perspective, but could be cost-increasing against the government
intention to control the increasing cost. The evaluation of
incremental cost-effectiveness ratio is the next step for further
assessment.
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